vimarsana.com

Latest Breaking News On - Fluid retention - Page 5 : vimarsana.com

Furosemide Seen as Safe for Preventing Newborn Lung Disease

Low-Sodium Diet Did Not Cut Clinical Events in Heart Failure

The #1 Danger Sign You re Developing Liver Disease, Says Science

The liver is one of the body's most crucial organs, responsible for detoxifying the blood, metabolizing macronutrients, and producing chemicals that enable essential bodily processes. And during this pandemic, many of us are not treating it properly: "Although national figures are not available, admissions for alcoholic liver disease at Keck Hospital of the University of Southern California were up 30% in 2020 compared with 2019, said Dr. Brian Lee, a transplant hepatologist who treats the condition in alcoholics," reports Kaiser Health News. “There’s been a tremendous influx,” Dr. Haripriya Maddur, a hepatologist at Northwestern Medicine, told the website. Read on to see the #1 danger sign—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had Coronavirus.The #1 Danger Sign Your Liver Is in Trouble is Fluid RetentionIf your liver isn't functioning properly, it can cause serious, even

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination

Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA ® and ZYTIGA ® plus prednisone (control arm). 1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.